Abstract
Towards the goal of producing fully human polyclonal antibodies (hpAbs or hIgGs) in transchromosomic (Tc) cattle, we previously reported that Tc cattle carrying a human artificial chromosome (HAC) comprising the entire unrearranged human immunoglobulin (Ig) heavy-chain (hIGH), kappa-chain (hIGK), and lambda-chain (hIGL) germline loci produced physiological levels of hIgGs when both of the bovine immunoglobulin mu heavy-chains, bIGHM and bIGHML1, were homozygously inactivated (bIGHM-/-, bIGHML1-/-; double knockouts or DKO). However, because endogenous bovine immunoglobulin light chain loci are still intact, the light chains are produced both from the hIGK and hIGL genomic loci on the HAC and from the endogenous bovine kappa-chain (bIGK) and lambda-chain (bIGL) genomic loci, resulting in the production of fully hIgGs (both Ig heavy-chains and light-chains are of human origin: hIgG/hIgκ or hIgG/hIgλ) and chimeric hIgGs (Ig heavy-chains are of human origin while the Ig light-chains are of bovine origin: hIgG/bIgκ or hIgG/bIgλ). To improve fully hIgG production in Tc cattle, we here report the deletion of the entire bIGL joining (J) and constant (C) gene cluster (bIGLJ1-IGLC1 to bIGLJ5-IGLC5) by employing Cre/loxP mediated site-specific chromosome recombination and the production of triple knockout (bIGHM-/-, bIGHML1-/- and bIGL-/-; TKO) Tc cattle. We further demonstrate that bIGL cluster deletion greatly improves fully hIgGs production in the sera of TKO Tc cattle, with 51.3% fully hIgGs (hIgG/hIgκ plus hIgG/hIgλ).
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Animals, Newborn
-
Antibodies, Monoclonal / immunology*
-
B-Lymphocytes / immunology
-
B-Lymphocytes / metabolism
-
Base Sequence
-
CHO Cells
-
Cattle
-
Cell Line
-
Chromosomes, Artificial, Human / genetics*
-
Cricetinae
-
Cricetulus
-
Female
-
Flow Cytometry
-
Gene Knockout Techniques*
-
Humans
-
Immunoglobulin G / genetics
-
Immunoglobulin G / immunology
-
Immunoglobulin Heavy Chains / genetics
-
Immunoglobulin Heavy Chains / immunology
-
Immunoglobulin kappa-Chains / genetics
-
Immunoglobulin kappa-Chains / immunology
-
Immunoglobulin lambda-Chains / genetics
-
Immunoglobulin lambda-Chains / immunology
-
Immunoglobulin mu-Chains / genetics
-
Immunoglobulin mu-Chains / immunology
-
Immunoglobulins / genetics*
-
Immunoglobulins / immunology*
-
Male
-
Molecular Sequence Data
-
Reverse Transcriptase Polymerase Chain Reaction
-
Sequence Homology, Nucleic Acid
Substances
-
Antibodies, Monoclonal
-
Immunoglobulin G
-
Immunoglobulin Heavy Chains
-
Immunoglobulin kappa-Chains
-
Immunoglobulin lambda-Chains
-
Immunoglobulin mu-Chains
-
Immunoglobulins
Grants and funding
This work was financed by internal funding of Hematech, Inc., which no longer exists and no longer has financial interest in the work. Hematech has transferred all of its business to Sanford Applied Biosciences, LLC. No current external funding sources for this study. Financial interest in this work is currently owned by Sanford Applied Biosciences, who did have a role in the decision to publish as well as the preparation of the manuscript. While it is considered beneficial to the interests of Sanford Applied Biosciences to publish this work, this consideration played no role in the study design, data collection and analysis and preparation of the manuscript. This is evidenced by the inclusion of now independent authors with no affiliation to Sanford Applied Biosciences.